Clinical trials: Phototherapy, open to volunteers
Graft-Versus-Host Disease, GVHD
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
- Conditions
- Graft-Versus-Host Disease, GVHD, Undefined
- Trial name
- NCT05675930
- Testing
- Photobiomodulation Therapy
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Parkinson Disease
Evaluation of Functional and Biochemical Effectiveness of a Strength Training Protocol in Parkinson's Disease
Parkinson's Disease (PD) is a complex neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons, which results in a range of motor symptoms such as tremor, rigidity, and bradykinesia, as well as…
- Trial name
- POWER-PD (NCT07095400)
- Testing
- strength training
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- Universidad Villanueva
Peripheral Artery Disease, Claudication, Intermittent
Red Light Treatment in Peripheral Artery Disease
Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (<.9 or >1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle.
- Conditions
- Peripheral Artery Disease, Claudication, Intermittent, Vasodilation
- Trial name
- NCT03203239
- Testing
- Red Light (670 nm energy), Octafluoropropane
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Peripheral Artery Disease (PAD)
Using Near-Infrared Light to Better Understand Peripheral Artery Disease
The goal of this study is to better understand how blood flows and how oxygen is utilized in the lower limbs of people who suffer from peripheral artery disease.
- Trial name
- NCT07313410
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The University of Texas at Arlington
Glaucoma, Diabetic Retinopathy (DR)
"My Eyes, My Light": Amar Chokh, Amar Alo
Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life.
- Conditions
- Glaucoma, Diabetic Retinopathy (DR), Hypertensive Retinopathy, Cataract
- Trial name
- ACA2 (NCT07135570)
- Testing
- Multimodal Screening for Eye Disease, cataract surgery
- Where
- Bangladesh
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Data Yakka, Inc.
Cutaneous Metastatic Melanoma
Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma
This device phase I/II, first in human, early feasibility study (EFS), open-label, single-arm trial aims to evaluate the safety, tolerability, and preliminary efficacy of Gold Nanorod (GNR)-enabled sub-ablative targeted…
- Trial name
- NCT06870994
- Testing
- Targeted Hyperthermia Therapy
- Volunteers
- 10 people
- Sponsor
- Sona Nanotech Inc
Basal Cell Carcinoma (BCC)
Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas
This research study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions.
- Trial name
- NCT06623201
- Testing
- aminolevulinic acid HCL (ALA), BLU-U device model 4170E
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nathalie Zeitouni
Unipolar Depression
Bright Light Therapy for Depressed Geriatric Inpatients
Bright light therapy has been shown to be effective for the treatment of both seasonal and non-seasonal unipolar depression as well as bipolar depression, primarily in outpatients under the age of 60.
- Trial name
- NCT07002554
- Testing
- Bright light therapy, dim red light
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
AL Amyloidosis
Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
This study aims to evaluate the use of teclistamab in systemic AL amyloidosis and answer whether teclistamab can improve the rate of complete hematological response. This is a single-arm, multi-center, prospective study.
- Trial name
- NCT06699394
- Testing
- Teclistamab (Tec)
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Tinnitus, Tinnitus, Subjective
External Therapy for Tinnitus Management
The goal of this remote interventional clinical study is to investigate the use of mild therapeutic hypothermia devices for the symptomatic relief of chronic tinnitus. The main aims of the study are: 1.
- Trial name
- NCT07017998
- Testing
- Cold pack-delivered mild therapeutic hypothermia
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Restorear Devices LLC
Neonatal Hyperbilirubinemia
Foot Reflexology and Massage in Neonates Receiving Phototherapy
Neonatal hyperbilirubinemia is a common condition in newborns and is frequently treated with phototherapy. In addition to standard treatment, non-pharmacological interventions such as massage and foot reflexology may help reduce…
- Trial name
- NCT07610811
- Testing
- Foot Reflexology, Body Massage, Phototherapy Device
- Where
- Turkey (Türkiye)
- Volunteers
- 105 people
- Sponsor
- Aydin Adnan Menderes University
Cocaine-Related Disorders
Bright Light Therapy During Inpatient Cocaine Detoxification
Cocaine is a major psychostimulant used to induce a state of euphoria, improved self-confidence and resistance to fatigue, with suppression of sleep.
- Trial name
- COKELUX (NCT07545798)
- Testing
- Medical light therapy device
- Where
- France
- Volunteers
- 256 people
- Sponsor
- Hôpital le Vinatier
Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
This study is researching a Regeneron drug called linvoseltamab ("study drug") alone compared to standard of care (SoC) combination to see if it can help treat participants who are newly diagnosed and previously untreated for…
- Trial name
- LINKER-AL1 (NCT07901725)
- Testing
- Linvoseltamab, Daratumumab, Bortezomib
- Volunteers
- 382 people
- Sponsor
- Regeneron Pharmaceuticals
Insomnia, Delayed Sleep Phase Disorder
Blue-blocking Glasses for Sleep Disorders in Child and Adolescent Psychiatry
Sleep problems and regulation difficulties are frequent in the child and adolescent psychiatry population. Insomnia and delayed sleep-wake phase disorders (DSPWD) are highly prevalent, and risk factors for developing more severe…
- Conditions
- Insomnia, Delayed Sleep Phase Disorder, Hyperarousal, Transdiagnostic Psychopathology
- Trial name
- BATCAT-pilot (NCT07433491)
- Testing
- Blue-blocking glasses (BB-glasses) or real darkness from 9 p.m. to desired wake-up time + night mode setting on mobile phone, Control
- Where
- 2 sites in Norway
- Volunteers
- 40 people
- Sponsor
- Helse Fonna
AL Amyloidosis, POEMS Syndrome
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome.
- Conditions
- AL Amyloidosis, POEMS Syndrome, Multiple Myeloma
- Trial name
- ALPS (NCT07448935)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Hand-foot Syndrome, Hand-foot Skin Reaction
Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction
Hand-foot syndrome (HFS) is a side effect of chemotherapy. HFS is characterized by redness, swelling, and pain on the palms of the hands and/or soles of the feet, which can progress to blistering.
- Trial name
- DermLight (NCT04979078)
- Testing
- Photobiomodulation therapy (PBMT)
- Where
- 2 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Jessa Hospital
Retinitis Pigmentosa
A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injection bilaterally every 6 weeks in patients with late-stage retinitis pigmentosa…
- Trial name
- ABACUS-2 (NCT06628947)
- Testing
- 100 μg KIO-301, 50 μg KIO-301
- Where
- 5 sites in Australia
- Volunteers
- 36 people
- Sponsor
- Kiora Pharmaceuticals, Inc.
Neonatal Hyperbilirubinemia, Rebound Hyperbilirubinemia
Predictors of Rebound Hyperbilirubinemia Study
## Brief Summary Neonatal hyperbilirubinemia is one of the most common causes of neonatal hospitalization and phototherapy treatment.
- Trial name
- NCT07694635
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Haseki Training and Research Hospital
Chronic Myeloproliferative Disorders, Leukemia
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT01137643
- Testing
- biologic sample preservation procedure, cytology specimen collection procedure
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Physial Disabilities
Examining the Health Impact of and Promoting Sitting Light Volleyball in the Greater Bay Area
The present study builds on the promising result of our SLVB pilot study with the aim to extend the works' impact by investigating the effectiveness of a SLVB intervention on the physical and psychological health outcomes in…
- Trial name
- NCT07164508
- Testing
- Sitting Light Volleyball Intervention, Group Seated Dance Intervention
- Where
- Hong Kong
- Volunteers
- 225 people
- Sponsor
- Education University of Hong Kong